Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Chapter
A Trial of ICRF-187 to Selectively Protect Against Chronic Adriamycin Cardiac Toxicity: Rationale and Preliminary Results of a Clinical Trial
The wide spectrum of anthracycline activity as well as the unique cumulative dose related cardiac toxicity pose a significant clinical challenge. These drugs, particularly doxorubicin (AdriamycinR), constitute so...